Anne E. Goodbody
Profile
Anne E.
Goodbody is Vice President of Drug Development for Vasogen, Inc. Dr. Goodbody has 20 years of experience in research and development in the biopharmaceutical industry.
She held various positions at Allelix, Inc., Resolution Pharmaceuticals, Bayer and Molecular Insight Pharmaceuticals, Inc. Dr. Goodbody received a graduate degree in Biochemistry from the University of Aberdeen and a PhD from the University of Cambridge, UK.
Former positions of Anne E. Goodbody
| Companies | Position | End |
|---|---|---|
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Corporate Officer/Principal | 22/10/2009 |
Training of Anne E. Goodbody
| University of Aberdeen | Undergraduate Degree |
| University of Cambridge | Graduate Degree |
Experiences
Positions held
Linked companies
| Private companies | 1 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
- Stock Market
- Insiders
- Anne E. Goodbody
